Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures.
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.
There is still a lack of lack of standardized treatment protocols for pulmonary embolism. This is mainly due to limited data and a lack of reliable risk assessments, one specialist explained.
Most EP clinical study data are from men, Anne Kroman, DO, explained in an interview. This is a significant problem, she said, because heart rhythm issues look quite different in women.
Sahil Parikh, MD, director of endovascular services, New York-Presbyterian, explains details from the big-data REAL-PE study comparing mechanical thrombectomy to ultrasound assisted catheter thrombolysis.
Anne Kroman, DO, PhD, assistant professor at Medical University of South Carolina (MUSC), explains mentoring efforts for women in EP and why it is important for patients to see more female electrophysiologists to help overcome barriers.
Emily Lau, MD, a women's health expert with Massachusetts General Hospital, thinks major changes are needed in how we diagnose CVD in women. "Our guidelines need to be more precise and offer sex-specific recommendations," she says.
In rural Oklahoma, double amputees due to untreated peripheral artery disease face mortality rates around 35% after one year and 60% after two. Jim Melton, DO, hopes his mobile cardiology clinics can make a difference for these patients.
Care teams gained significant momentum in the early days of TAVR. Now, however, they are being used to address a wide variety of cardiovascular concerns.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
